Neoplasms, Germ Cell and Embryonal  >>  sagopilone (BAY86-5302)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sagopilone (BAY86-5302) / Bayer
NCT00424060 / 2006-001659-37: Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma

Completed
2
38
Europe
sagopilone, fluorescence in situ hybridization, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study
European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
08/07
 
NCT00397072: Epothilone in Recurrent Glioblastoma Patients

Completed
2
15
Europe
ZK 219477
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Glioblastoma
03/08
12/08
NCT00598507: Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma

Completed
2
35
US
ZK-EPO, EpothiloneZK, ZK 219477, Sagopilone
H. Lee Moffitt Cancer Center and Research Institute, Bayer
Melanoma
01/13
01/13

Download Options